Condition: Sepsis · Septic Shock · Immunoparalysis in Septic Shock · Sponsor: Artcline GmbH
The objectives of this registry study are to: 1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3. Identify potential sub-groups, assess their risk-benefit- and safety profile. 4. Changes in SOFA score D0 to SOFA Score D7.
This description comes directly from the study's public registry record.
Jens Altrichter, Dr. med. · +49 381 440 703 0 · jens.altrichter@artcline.de
Judith Hey, M. Sc. · +49 1772216033 · judith.hey@artcline.de
Always discuss trial participation with your own doctor first.
| Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin | Magdeburg, Germany | Recruiting |
| Johannes Wesling Klinikum, Universitätsklinik für Anästhesiologie, Intensiv & Notfallmedizin | Minden, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07388628